<DOC>
	<DOCNO>NCT02680249</DOCNO>
	<brief_summary>Three way crossover study assess bioavailability 656 fed fast condition .</brief_summary>
	<brief_title>Food Effect Study CTP-656 Healthy Male Volunteers</brief_title>
	<detailed_description>This study assess healthy male subject solid oral dose formulation CTP-656 fast fed condition . Primary : • To characterize relative bioavailability pharmacokinetic profile single 150 mg solid oral dose CTP-656 healthy volunteer fast , feed low-fat fed moderate-fat condition . Secondary : - To characterize pharmacokinetic profile metabolites CTP-656 follow single 150 mg solid oral dose CTP-656 healthy volunteer fast , feed low-fat fed moderate-fat condition . - To assess safety tolerability follow single 150 mg solid oral dose CTP-656 healthy volunteer fast , feed low-fat fed moderate-fat condition .</detailed_description>
	<criteria>Healthy adult 18 50 year age , inclusive Body weight ≥ 50 kg BMI within range 18 30 kg/m2 , inclusive , screen History clinically significant central nervous system ( eg , seizure ) , cardiac , pulmonary , metabolic , renal ( include nephrolithiasis ) , hepatic , include history Gilbert 's syndrome gastrointestinal ( GI ) condition PR interval ≥ 220 msec QRS duration ≥ 120 msec QTcF interval &gt; 450 msec obtain screen visit prior first dose study drug Liver function test great upper limit normal . Positive blood screen human immunodeficiency virus ( HIV antibody ) , hepatitis B virus surface antigen , hepatitis C virus antibody screen Urinalysis positive great trace blood , protein glucose A positive screen alcohol , drug abuse , tobacco use . Inability comply dietary restriction study participation . Donation blood collection acute loss blood prior screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Safety , Bioavailability Pharmacokinetics</keyword>
</DOC>